Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mXELOXIRI plus targeted therapy for unresectable mCRC
NCT04160416Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, irinotecan, cetuximab and bevacizumab in colorectal cancer (metastatic) (mCRC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Objective Response Rate at 36 months, Progression-Free Survival at 18 months and 3 more. Status: unknown.
02
Drugs
capecitabineoxaliplatinirinotecancetuximabbevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04160416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160416.